Mavorixafor trihydrochloride
| CAS No. | 2309699-17-8 | Cat. No. | BCP32916 |
| Name | Mavorixafor trihydrochloride | ||
| Synonyms | Mavorixafor 3HCl;AMD-070 trihydrochloride;AMD070 trihydrochloride; | ||
| Formula | C21H30Cl3N5 | M. Wt | 458.86 |
| Description | Mavorixafor is an orally bioavailable and potent CXCR4 inhibitor. AMD11070 is an antagonist of SDF-1α ligand binding (IC50 = 12.5 ± 1.3 nM), inhibits SDF-1 mediated calcium flux (IC50 = 9.0 ± 2.0 nM) and SDF-1α mediated activation of the CXCR4 receptor as measured by a Eu-GTP binding assay (IC50 =39.8 ± 2.5 nM) or a [(35)S]-GTPγS binding assay (IC50 =19.0 ± 4.1 nM), and inhibits SDF-1α stimulated chemotaxis (IC50 =19.0 ± 4.0 nM). AMD11070 abrogates melanoma cell migration and is significantly more effective than AMD3100. AMD11070 represents a novel therapeutic strategy for both B-RAF wild-type and mutated melanomas. | ||
| Related Products | 558447-26-0（Mavorixafor） 880549-30-4（Mavorixafor hydrochloride） | ||
| Pathways | GPCR/G Protein | ||
| Targets | CXCR | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.